{"id":"W2149286249","doi":"10.1158/1078-0432.ccr-06-1165","title":"A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Calcitriol; Gefitinib; Medicine; Pharmacology; Pharmacokinetics; Pharmacodynamics; Epidermal growth factor receptor; Tyrosine-kinase inhibitor; Vandetanib; Protein kinase B; Internal medicine; Dosing; Endocrinology; Tyrosine kinase; Cancer; Chemistry; Receptor; Signal transduction; Vitamin D and neurology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001304115,0.001518912,0.002724308,0.0004707833,0.0005629368,0.001051376,0.0007624657,0.001083888,0.001347725],"category_scores_gemma":[0.001169535,0.0006813733,0.001161381,0.0004764755,0.001299725,0.0007433196,0.0002991642,0.002994211,0.0004554307],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001246753,"about_ca_system_score_gemma":0.001793862,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008863325,"about_ca_topic_score_gemma":0.001452346,"domain_scores_codex":[0.9992804,0.0003167352,0.00003357733,0.000132076,0.0001143744,0.0001229201],"domain_scores_gemma":[0.9991073,0.0001617334,0.0002268277,0.00007492464,0.00005120377,0.0003780301],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5034551,0.117851,0.02541423,0.0007854079,0.001798498,0.001117008,0.0007628324,0.008474469,0.1882132,0.0004047395,0.002995897,0.1487276],"study_design_scores_gemma":[0.2159769,0.7403912,0.02239354,0.00002529492,0.00050246,0.0009784815,0.00009713711,0.003265573,0.01357883,0.0001769691,0.002559675,0.00005401166],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996278,0.001052007,0.0006318307,0.0001769454,0.0000414304,0.0009786343,0.0001881688,0.00005925073,0.0005937067],"genre_scores_gemma":[0.9958212,0.0005129175,0.001440634,0.000178583,0.00009357139,0.0009206094,0.0004268725,0.00001799027,0.0005875201],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002724308,"threshold_uncertainty_score":0.009045839,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06016743687366678,"score_gpt":0.480103932089061,"score_spread":0.4199364952153942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}